This report presents three cases of atypical degenerative dementias in order to illustrate challenges associated with the use of biologic markers of Alzheimer's disease (AD) for diagnosis and management. Clinical diagnostic methods followed the NINCDS-ADRDA criteria for AD. Additional diagnostic studies included serial neurocognitive testing, MRI, neuroSPECT, ApoE genotyping, and a CSF assay of tau and beta-amyloid 42 . For patient 1, both the clinical and biologic markers were consistent with AD. The patient was diagnosed with AD with a high degree of confidence, even though the base rate of nonfamilial AD at this age group (<55 years) is exceedingly rare. This case argues favorably for the use of biologic markers to aid in confirming a diagnosis in an atypical dementia. Patient 2 met the NINCDS-ADRDA criteria for AD, although with less confidence. Neurocognitive data indicated a progressive right hemispheric syndrome, insight was preserved, and ApoE was 3/3, but tau concentrations and beta-amyloid 42 were highly consistent with cut-offs for AD; the differential fell on the Pick's disease/frontotemporal degeneration spectrum. Patient 3 had no clinical evidence of the disease, even when evaluated via extensive neurocognitive testing over a 2-year interval. However, ApoE was 4/4, and CSF assay of tau and beta-amyloid 42 were within the AD range. Therefore, while the CSF assay of tau and beta-amyloid 42 markers was confirmatory of AD, each case was highly atypical. Results illustrate the lack of normative data available when using biologic markers for highly atypical cases, calling into question their usefulness for such patients. These cases illustrate * Corresponding author. the interplay between neuropsychological and biological markers in establishing neurodegenerative diagnoses.
Introduction
Alzheimer's disease (AD) is diagnosed clinically by first identifying dementia and then eliminating all other possible causes of the dementia (McKhann et al., 1984) . Recent rigorous applications of the clinical diagnostic criteria of probable AD have resulted in 88 and 96% agreement between clinical and the final pathologic diagnosis (Klatka, Schiffer, Powers, & Kazee, 1996; Kosunen et al., 1996) . The diagnosis of definite AD is made when the patient fulfills the clinical criteria and histopathologic features that include "high" density of senile plaques composed of the ␤-amyloid peptide and neurofibrillary tangles comprised of the microtubule-associated protein tau (Khachaturian, 1985; McKhann et al., 1984; Wisniewski, Rabe, Zigman, & Silverman, 1989) .
Major advances in the molecular understanding of AD have implicated several different chromosomal abnormalities (on chromosomes 1, 14, 19, and 21) thought to be associated with the development of this disorder. Research suggests that the pathogenesis results in similar histopathologic changes, although it should be noted that at least half of all cases of AD lack a genetic contribution (Plassman & Breitner, 1996) . One area of increased recent attention has been the interplay between genetic/environmental factors in the pathogenesis of AD. Some researchers contend that the final clinical-pathological endpoint is derived from different combinations of events (Hardy & Higgins, 1992) .
The incorporation of findings from the basic sciences within the clinical setting can be confusing. For example, in the past decade, biologic research on AD has focused on amyloid protein found in the senile plaque and the tau protein of the neurofibrillary tangle. There has been enthusiasm regarding the potential clinical application of biologic markers in the diagnostic process (Andreasen et al., 2001; Galasko et al., 1998; Growdon, 1999; Terajima et al., 1996; Younkin, 1995) . Specifically, a new commercially available biologic marker of AD includes apolipoprotein E e4 (ApoE) genotyping combined with CSF tau protein and beta-amyloid 42 analysis (Athena Neuroscience Inc., ADmark TM Assays, 1996) . It has been found that the incremental lifetime risk of developing AD based on positive ApoE genotyping is a 14% increased risk and −6% for a negative result. This finding must be kept in perspective since survival from age 65 to 85 carries a 20-30-fold increased risk of developing AD (Seshadri, Drachman, & Lippa, 1995) . Roses (1995) has shown that in cases presenting with dementia where the likelihood of AD is 66%, with one 4 allele the odds of AD are increased to 81%, and with 2 e4 alleles, the odds are increased to about 94%. The consensus statement, however, from the American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer's disease (1995) warns against routine ApoE screening citing that: (1) the e4 allele is not necessary for the development of AD (at least 35-50% of persons with AD do not carry an e4 allele), (2) ethnicity and/or racial origin may affect sensitivity, (3) the e4 allele may be present in other forms of dementia, and (4) a positive or negative result should not exclude an exhaustive diagnostic work-up for reversible dementias.
Cerebrospinal fluid (CSF) screening of tau and beta-amyloid 42 (e.g., Galesko et al., 1998; Seshadri et al., 1995; Younkin, 1995) is the newest commercially available biologic marker of Alzheimer disease. The combination of high tau (i.e., >420 pg/ml) and low beta-amyloid 42 (i.e., <1240 pg/ml) has a sensitivity of greater than 95% in demented >60-year-old patients and a specificity of greater than 60% (Athena Neuroscience Inc., ADmark TM Assays). According to the manufacturer, the clinical application of biologic markers is a method for "greater certainty in AD diagnosis and prognosis." Limited empirical experience is available on the potential application of this biologic marker in the clinical setting, especially with atypical cases of dementia. Moreover, recently published practice parameters for the diagnosis of dementia by the American Academy of Neurology (Knopman et al., 2001) indicate as a practice guideline that there are no CSF or other biomarkers recommended for routine use in determining the diagnosis of AD at this time.
To highlight the issues involved in diagnosing AD, we contrast three atypical cases where the biological marker of Alzheimer disease was used to help in the diagnostic formulation. These cases not only illustrate the pros and cons of using biological markers, but also highlight the interplay between biomarkers and neuropsychological studies in establishing diagnoses.
Methods

Subjects
Three subjects were selected from a pool of patients presenting at a University Hospital Ambulatory Neurology clinic. Each patient presented with complaints of memory difficulty. Diagnostic formulation followed and extended upon the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association consensus conference diagnostic guidelines (McKhann et al., 1984) .
Materials and procedure
The neurologic evaluation procedure consisted of bedside physical and neurologic examinations. Serial standard blood chemistry profiles where performed. CSF tau and beta-amyloid 42 concentrations (Athena Neuroscience Inc., ADmark TM Assays) and ApoE genotyping were obtained. Neuroradiographic imaging included MRI and neuroSPECT studies. Neurocognitive evaluation was conducted using the CERAD neuropsychological battery (Morris et al., 1989) , the Weschler Adult Intelligence Scale-Revised (Wechsler, 1981) , the Weschler Memory Scale-Revised (Wechsler, 1987) and other widely used neuropsychological tests including the Visual Cancellation Test (Mesulam, 1985) , Draw-a-Clock Perceptual Test (Freedman et al., 1994) , Trail Making Test (Lezak, 1995) , Geriatric Mood Inventory (Yesavage et al., 1983) , and the Unawareness Questionnaire (Wagner, Spangenberg, Bachman, & O'Connell, 1997) .
In addition, the patient's spouse completed the Memory and Behavior Problem Checklist (Teri et al., 1992) .
Results
Case presentation-subject #1
Case 1 is a 50-year-old female with approximately a 2-3-year history of insidious onset memory complaints. Unusual for AD, the patient was keenly aware of her memory problems and mental status decline. Additionally, she admitted to elaborate strategies she used to cover-up her memory deficits by changing the subject. She had lost her job as an office manager of 20 years 2 years earlier because of her mental confusion. At the time of examination, the patient was living at home and was independent for her activities of daily living (ADLs), but needed assistance from her husband for shopping, complex meal preparation, and home finances. Her medical history was positive for mitral value prolapse and she was status posthysterectomy. She was on sertraline without effect for her memory problem. Her family history was negative for degenerative dementias. She had a high school education, was married with two grown children, and had worked as an office manager for 20 years prior to being let go secondary to her mental confusion.
The neurologic examination was negative except for mental confusion noted during bedside examination. The metabolic panel was normal. HIV and VDRL were negative. Radiographic imaging with MRI was negative and a neuroSPECT study showed bilateral hypoperfusion in the posterior occipital and superior temporal lobes. An EEG was normal. Neurocognitive examination showed a focal disturbance in memory, disorientation, unusually good awareness of cognitive deficit, and other nonspecific higher cortical losses. These findings were consistent with the neuroSPECT (see Table 1 ). Dementia severity was rated as clinical dementia rating (Hughes, Berg, Danziger, Coben, & Martin, 1982) as 2.0 or moderate dementia severity. ApoE was 3/4, and CSF analysis revealed elevated tau (1046 pg/ml) and low beta-amyloid 42 (329 pg/ml).
Diagnostic formulation
The disease course, laboratory studies, and neurocognitive findings showed a pattern of deficits that met the NINCDS-ADRDA criteria for a clinical diagnosis of probable AD. While all clinical findings were consistent with AD, the base rate of AD with a nonfamilial history is exceedingly rare for this age. ApoE genotyping and beta-amyloid 42 and tau concentrations analysis from the CSF were consistent with AD. The diagnostic formulation was of a probable early onset nonfamilial AD.
Case presentation-subject #2
Case 2 was of a 66-year-old male with approximately a 2-3-year history of insidious complaints of motor dyscoordination, mental confusion, and memory loss. The patient's wife added the complaint of progressive symptoms of becoming tangled while dressing and lost while driving. His past medical history was noncontributory and his medications included theophylline. His family history was negative for neurologic disease. His social history included a GED and a career in the Air Force in an administrative position. His second career was at a research facility where he took part in the construction of experimental prostheses. He had a remarkable mechanical aptitude and had a workshop at home. The neurologic examination was significant for left drift of outstretched arms and asymmetrical hyper-reflexia on the left with occasional myoclonic jerks with the left greater than right. He also extinguished to simultaneous tactile stimulation on the left, but showed no visual extinction. The metabolic panel was normal. HIV and VDRL were negative. Radiographic imaging with MRI was significant for prominent diffuse atrophy. A neuroSPECT showed focal hypometabolism in the right parietal and temporal lobes. An EEG was normal. Bedside examination showed a remarkable dressing apraxia and topological disorientation that was progressive over the interval. Serial neurocognitive examination showed a progressive decline in objective scores with a pattern of scores remarkable for a progressive right cerebral hemispheric syndrome. The neurobehavioral findings were consistent with the neuroSPECT. Secondary memory and orientation were relatively spared. Serial evaluation showed progressive right hemispheric deficits with relatively stable memory (see Table 2 ). Dementia severity showed a clinical dementia rating score (Hughes et al., 1982) in the mild dementia severity range (CDR 1.0). ApoE genotyping revealed a 3/3, while CSF analysis indicated elevated tau (931 pg/ml) and low beta-amyloid 42 (477 pg/ml). 
Diagnostic formulation
The history, laboratory studies, and finding of dementia met the NINCDS-ADRDA criteria for the clinical diagnosis of AD. The neurocognitive findings, however, were highly atypical of AD showing a pattern of deficits consistent with a lateralized right hemispheric syndrome that was progressive in nature and secondary memory, orientation, and insight that were relatively preserved-atypical of AD. Similarly, the patient and spouse strongly argued that his dementing condition was unlike anything described in the literature; they had read extensively about AD. Yet, the beta-amyloid 42 and tau concentrations in the CSF were highly consistent with cut-offs for AD, although the punitive 4 alleles were absent. The diagnostic formulation for this case was of a probable highly atypical variant of AD. Interestingly, the patient had an insidious progressive loss of right hemispheric cognitive abilities that also is highly atypical of AD.
Case presentation-subject #3
Case 3 was of a 62-year-old male initially seen because of a fear that he had Alzheimer disease. He complained of forgetting names and minor word finding problems. However, in spite of this, he was functional in his vocational and social spheres. He had no significant medical history and was not on any medications. His family history was positive for one parent having possible late onset Alzheimer disease. He had a college education and held a professional position. The patient was seen for serial evaluations over a 2-year interval.
The neurologic examination was normal, as was the metabolic panel. HIV and VDRL were negative. Radiographic imaging with MRI was significant for minor diffuse cortical atrophy. A neuroSPECT showed focal hypometabolism in the left parietal and bilateral temporal lobes. He ruled out for CNS infection. The beta-amyloid 42 (812 pg/ml) and tau (1078 pg/ml) concentrations in the CSF were highly consistent with cut-offs for AD. His ApoE of 3/4 was likewise suggestive. Serial neurocognitive examination (see Table 3 ) showed intact cognitive function across multiple domains without progression.
Diagnostic formulation
The laboratory studies conflicted with the clinical findings and course. The laboratory findings are highly consistent with AD. The clinical findings were of normal cognition and the clinical course was stable. Intellect, secondary memory, orientation, and insight remained normal and stable over a 2-year interval. At 2-year follow-up, the patient failed evidence of even questionable dementia (CDR 0.5) (Hughes et al., 1982) . The diagnostic formulation for this case was of someone at high risk of developing Alzheimer disease.
Discussion
Do biologic markers increase diagnostic confidence in Alzheimer disease? What is the role of neuropsychological testing in dementia? Clinicians should be realistic when considering the use of such markers. Specifically, diagnostic confidence of AD when using the NINCDS-ADRDA clinical criteria (Klatka et al., 1996; Kosunen et al., 1996) ranges from around 88 to 96%. The diagnostic confidence of the biological marker of AD (Athena Neuroscience Inc., ADmark TM Assays) is around 95%. Given the high diagnostic confidence of the clinical diagnosis, the need for a biological marker seems the greatest only in cases of atypical dementias. Yet, as was illustrated, our data suggest mixed results. In some cases of atypical degenerative dementias, the additional use of a biological marker may increase the confidence of the diagnosis of AD. In other cases, the additional use of a biological marker may raise more questions than provide answers. Unfortunately, it also is the case that where the need for a biological marker is the greatest (early onset AD, distinguishing AD from other atypical degenerative dementias, etc.), the sensitivity/specificity data are sparse.
In case 1, there was a clear indication to pursue further diagnostics. The clinical confidence of an AD diagnosis if the patient were elderly would have been in the 85-90% plus range.
Figures for clinical confidence of the NINCDS-ADRDA diagnostic criteria in a 50-year-old, with no family history are unknown, but probably much lower. In this case, positive biologic indices presumably increased our diagnostic confidence significantly and the marker was of value.
In case 2, the situation is more vexing. It would appear that the positive biologic marker for AD increased the confidence of the diagnosis of AD. However, the clinical history and neuropsychological findings were in such contrast with the biologic indices that questions about the specificity of the CSF assay with reference to other atypical cortical degenerative dementias remain unanswered. Clinical-neuropathological investigations of the use of biological markers in such atypical cases of degenerative dementias are needed before the use of such markers can be recommended.
In case 3, all biomarkers were strongly suggestive of Alzheimer disease, although the clinical correlate and course were negative for this disorder. In this case, biologic markers were not helpful clinically other than identifying a risk factor. We are concerned about this patient's functioning given these positive indices, as we believe that he is at increased risk for developing AD. This case illustrates the value of ongoing neuropsychological surveillance.
Can biologic markers be used to reduce the expenses associated with a costly dementia work-up? By definition, the NINCDS-ADRDA (McKhann et al., 1984) diagnosis of "definite AD" must meet the clinical criteria of "probable AD," plus have histopathologic confirmation. Histopathologic evidence of the disease alone is insufficient to diagnose Alzheimer disease. There are sufficient numbers of cases with histopathologic signs of AD that did not develop the clinical manifestations of the disease and vice versa (Mirra, Hart, & Terry, 1993) . Perhaps even more problematic is the issue of comorbid disease(s). Concurrent vascular disease, iatrogenic medication complications, and depression are some of the most frequent causes that are at least partially reversible or arrestable, which would not be detected if only an AD biologic marker were used. At present it would seem biologic markers of AD might primarily be useful only as a selective adjunct diagnostic test for select cases. Indeed, the American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer's disease (1995) maintain that especially in asymptomatic cases, the clinical use of ApoE as a screening tool is of questionable value. Similarly, the American Academy of Neurology has recently issued a practice guideline stating that there are no CSF or other biomarkers recommended for routine use in determining the diagnosis of AD at this time (Knopman et al., 2001) .
What role do biologic markers play in clinical management? In general, a biologic marker will not provide information about when the disease will manifest (if ever), expected natural history, or current dementia severity. While AD generally follows a predictable course, there is a growing recognition that many cases of AD do not (Caselli & Jack, 1992; Kertesz & Munoz, 1998; Snowden, Nealy, & Mann, 1996; Weintraub & Mesulam, 1994) . As was illustrated in case 2, generic counseling to patient/family about the likely clinical expression would be of limited value. Likewise, other practical questions including safety interventions related to the patient's competencies to drive, manage finances, safety to pursue vocational interests, etc. cannot be addressed based on biologic findings alone. Similarly, it is unknown whether the atypical dementias, as seen in case 2, would respond to acetylcholinestearse inhibitors such as donepezil, gabapentine, or rivastigmine.
We conclude that the ApoE genotyping and markers of tau and beta-amyloid 42 have mixed efficacy for diagnosis and management in dementia cases with an atypical presentation. This is particularly the case given the lack of enhanced value that biological markers add to the neuropsychological findings. Further, the value of serial neuropsychological investigation in heightening diagnostic confidence cannot be overemphasized and is clearly now becoming recognized as a standard by which early diagnosis can be established. Therefore, cautious optimism is warranted in the use of biologic markers in the diagnosis of AD. There is a need to demonstrate the sensitivity and specificity of biologic markers when measured against other histopathologically proven cases of atypical AD and non-AD degenerative dementias. Minimal increase in diagnostic confidence and high rates of false negatives are some of the shortcomings that argue against usefulness of biologic markers for routine clinical evaluations.
